Vaccination with a chaperone complex based on PSCA and GRP170 adjuvant enhances the CTL response and inhibits the tumor growth in mice

Vaccine

Volumn 28, Issue 38, 2010, Pages 6333-6337

  Huo, Wenqian ^a   Ye, Jin ^a   Liu, Rongrong ^a   Chen, Jin ^a   Li, Qiansheng ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chaperone complex; GRP170; Prostate cancer; PSCA

Indexed keywords

CANCER VACCINE; CHAPERONE; CHROMIUM 51; GAMMA INTERFERON; GRP170 PROTEIN; HEAT SHOCK PROTEIN; PROSTATE STEM CELL ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; GROWTH INHIBITION; LIFESPAN; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR CELL; TUMOR GROWTH; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; GLYCOPROTEINS; GPI-LINKED PROTEINS; HSP70 HEAT-SHOCK PROTEINS; IMMUNODOMINANT EPITOPES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MOLECULAR CHAPERONES; NEOPLASM PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77955658389     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.093     Document Type: Article

References (41)

1. Lalani el N., Laniado M.E., Abel P.D. Molecular and cellular biology of prostate cancer. Cancer Metastasis Rev 1997, 16:29-66.
2. Reiter R.E., Gu Z., Watabe T., Thomas G., Szigeti K., Davis E., et al. Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998, 95:1735-1740.
3. Gu Z., Thomas G., Yamashiro J., Shintaku I.P., Dorey F., Raitano A., et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000, 19:1288-1296.
4. Lin H.Y., Masso-Welch P., Di Y.P., Cai J.W., Shen J.W., Subjeck J.R. The 170kDa glucose-regulated stress protein is an endoplasmic reticulum protein that binds immunoglobulin. Mol Biol Cell 1993, 4:1109-1119.
5. Chen X., Easton D., Oh H.J., Lee-Yoon D.S., Liu X., Subjeck J. The 170kDa glucose regulated stress protein is a large HSP70-, HSP110-like protein of the endoplasmic reticulum. FEBS Lett 1996, 380:68-72.
6. Rachel A., Tyson J.R., Stirling C.J. A novel subfamily of Hsp70s in the endoplasmic reticulum. Trends Cell Biol 1997, 7:277-282.
7. Easton D.P., Kaneko Y., Subjeck J.R. The hsp110 and Grp1 70 stress proteins: newly recognized relatives of the Hsp70s. Cell Stress Chaperones 2000, 5:276-290.
8. Kuznetsov G., Chen L.B., Nigam S.K. Multiple molecular chaperones complex with misfolded large oligomeric glycoproteins in the endoplasmic reticulum. J Biol Chem 1997, 272:3057-3063.
9. Dierks T., Volkmer J., Schlenstedt G., Jung C., Sandholzer U., Zachmann K., et al. A microsomal ATP-binding protein involved in efficient protein transport into the mammalian endoplasmic reticulum. EMBO J 1996, 15:6931-6942.
10. Craven R.A., Egerton M., Stirling C.J. A novel Hsp70 of the yeast ER lumen is required for the efficient translocation of a number of protein precursors. EMBO J 1996, 15:2640-2650.
11. Spee P., Subjeck J., Neefjes J. Identification of novel peptide binding proteins in the endoplasmic reticulum: ERp72, calnexin, and grp170. Biochemistry 1999, 38:10559-10566.
12. Tyson J.R., Stirling C.J. LHS1 and SIL1 provide a lumenal function that is essential for protein translocation into the endoplasmic reticulum. EMBO J 2000, 19:6440-6452.
13. Wang X.Y., Kazim L., Repasky E.A., Subjeck J.R. Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity. J Immunol 2001, 166:490-497.
14. Oh H.J., Chen X., Subjeck J.R. Hsp110 protects heat-denatured proteins and confers cellular thermoresistance. J Biol Chem 1997, 272:31636-31640.
15. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23-47.
16. Crawford E.D., Rosenblum M., Ziada A.M., Lange P.H. Hormone refractory prostate cancer. Urology 1999, 54:1-7.
17. Hillman G.G., Triest J.A., Cher M.L., Kocheril S.V., Talati B.R. Prospects of immunotherapy for the treatment of prostate carcinoma-a review. Cancer Detect Prev 1999, 23:333-342.
18. Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14:1756-1764.
19. Kim J.J., Trivedi N.N., Wilson D.M., Mahalingam S., Morrison L., Tsai A., et al. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. Oncogene 1998, 17:3125-3135.
20. Hodge J.W., Schlom J., Donohue S.J., Tomaszewski J.E., Wheeler C.W., Levine B.S., et al. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): safety and immunogenicity in a non-human primate. Int J Cancer 1995, 63:231-237.
21. Saffran D.C., Reiter R.E., Jakobovits A., Witte O.N. Target antigens for prostate cancer immunotherapy. Cancer Metastasis Rev 1999, 18:437-449.
22. Fong L., Ruegg C.L., Brockstedt D., Engleman E.G., Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 1997, 159:3113-3117.
23. Murphy G.P., Tjoa B.A., Simmons S.J., Jarisch J., Bowes V.A., Ragde H., et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999, 38:73-78.
24. Zhang S., Zhang H.S., Reuter V.E., Slovin S.F., Scher H.I., Livingston P.O. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998, 4:295-302.
25. Pavlenko M., Roos A.K., Lundqvist A., Palmborg A., Miller A.M., Ozenci V., et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004, 91:688-694.
26. Eder J.P., Kantoff P.W., Roper K., Xu G.X., Bubley G.J., Boyden J., et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000, 6:1632-1638.
27. Murphy G., Tjoa B., Ragde H., Kenny G., Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996, 29:371-380.
28. Argani P., Rosty C., Reiter R.E., Wilentz R.E., Murugesan S.R., Leach S.D., et al. Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res 2001, 61:4320-4324.
29. Amara N., Palapattu G.S., Schrage M., Gu Z., Thomas G.V., Dorey F., et al. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res 2001, 61:4660-4665.
30. Saffran D.C., Raitano A.B., Hubert R.S., Witte O.N., Reiter R.E., Jakobovits A. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci USA 2001, 98:2658-2663.
31. Srivastava P.K., Udono H. Heat shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol 1994, 6:728-732.
32. Srivastava P.K., Udono H., Blachere N.E., Li Z. Heat shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 1994, 39:93-98.
33. Blachere N.E., Srivastava P.K. Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors. Semin Cancer Biol 1995, 6:349-355.
34. Hightower L.E. Heat shock, stress proteins, chaperones, and proteotoxicity. Cell 1991, 66:191-197.
35. Srivastava P.K., DeLeo A.B., Old L.J. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci USA 1986, 83:3407-3411.
36. Srivastava P.K., Heike M. Tumor-specific immunogenicity of stress-induced proteins: convergence of two evolutionary pathways of antigen presentation?. Semin Immunol 1991, 3:57-64.
37. Blachere N.E., Udono H., Janetzki S., Li Z., Heike M., Srivastava P.K. Heat shock protein vaccines against cancer. J Immunother Emphasis Tumor Immunol 1993, 14:352-356.
38. Srivastava P.K. Heat shock proteins in immune response to cancer: the fourth paradigm. Experientia 1994, 50:1054-1060.
39. Blachere N.E., Li Z., Chandawarkar R.Y., Suto R., Jaikaria N.S., Basu S., et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997, 186:1315-1322.
40. Park J., Easton D.P., Chen X., MacDonald I.J., Wang X.Y., Subjeck J.R. The chaperoning properties of mouse grp170, a member of the third family of hsp70 related proteins. Biochemistry 2003, 42:14893-14902.
41. Wang X.Y., Kazim L., Repasky E.A., Subjeck J.R. Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease. Int J Cancer 2003, 105:226-231.